Search filters

Filters
Clear All

Phase

  • 2
  • 4
  • 1
  • 5
  • 12
  • 7
  • 12

Found 12 Gliomas trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 ONC201 in recurrent high-grade glioma
18 years - 99 years
All genders
Phase 2
This is a phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects for this study will be recruited from the patient population that present to the Penn Brain tumor center- Department of Neurosurgery or Department of Medicine division of Hematology/ Oncology for evaluation and treatment …
99 years or below
All genders
Phase 2
Primary Objectives Cohort 1: To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when administered with cemiplimab among recurrent malignant glioma participants. Cohort 2: To determine if neoadjuvant immune checkpoint blockade (ICB) with ASP8374, cemiplimab and the combination of ASP8374 plus cemiplimab will induce …
99 years or below
All genders
Phase 1
The outlined research study is not of therapeutic intent, involving only the collection of blood, cerebrospinal fluid, and tissue samples to evaluate pharmacokinetics and resistance.
99 years or below
All genders
Phase 2
The purpose of this research study will be to evaluate the safety and effectiveness of two investigational drugs, All-trans retinoic acid (ATRA) and Retifanlimab (anti-PD1 monoclonal antibody), in treating recurrent IDH-mutant gliomas. Objective radiographic response (CR + PR + MR) using Response Assessment in Neuro-Oncology (RANO) criteria by measurable disease …
 A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to temporarily mediate Blood-Brain Barrier Disruption (BBBD) in patients with suspected infiltrating glioma in the setting of planned surgical interventions
18 years - 99 years
All genders
The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and feasibility of using ExAblate Model 4000 Type-2 Neuro-System as a tool to disrupt the blood brain barrier in a temporary and localized fashion in patients with suspected infiltrating glioma undergoing planned surgical interventions.
 Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naive and Bevacizumab Resistant Recurrent Glioblastoma
18 years - 99 years
All genders
Phase 2
This is a multicenter, open-label, phase II trial of pembrolizumab plus re-irradiation among recurrent glioblastoma patients enrolled to two parallel, non-comparative treatment arms including patients who are bevacizumab naïve (Arm A, n=30) and patients who are bevacizumab-resistant (Arm B, n=30). All subjects must have histologically confirmed World Health Organization (WHO) …
 AGIOS
18 years - 99 years
All genders
Phase 3
Normal 0 false false false EN-US X-NONE X-NONE  This research study is a phase 3, double-blind clinical trial to assess the efficacy of Agios versus placebo in subjects with residual or recurrent Grade 2 oligodendroglioma and astrocytoma with an IDH1 or IDH2 mutation who have undergone surgery as their only …
 Circulating Biomarkers for Glioma
18 years - 99 years
All genders
Subjects will be recruited from the Radiation Oncology and Neurosurgery practices at the Hospital of the University of Pennsylvania. The treating radiation oncologist will determine if the patient is a potential research candidate and has the capacity to consent. The goal of this study is to collect and analyze blood …
99 years or below
All genders
Phase 1
Interventional
This study is being done to determine how well the study drug, BGB-290, gets into the brain tumor and to confirm if we can continuously and safely give BGB-290 and temozolomide as a combination treatment after surgery. We are testing a dose of temozolomide once a day combined with the …
99 years or below
All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
1 - 10 of 12